ALK-Abello A/S - Stock

ALK-Abello A/S Equity 2024

ALK-Abello A/S Equity

4.45 B DKK

ALK-Abello A/S Dividend yield

3.48 %

Ticker

ALK B.CO

ISIN

DK0060027142

WKN

A0H0J1

In 2024, ALK-Abello A/S's equity was 4.45 B DKK, a 11.51% increase from the 3.99 B DKK equity in the previous year.

ALK-Abello A/S Aktienanalyse

What does ALK-Abello A/S do?

ALK-Abello A/S is a Danish company specializing in the production of allergy-based products and therapies. It was founded in 1923 by Dr. H. C. Harald Petersen and is headquartered in Hørsholm, Denmark. The company's history began with Dr. Petersen's discovery that allergens could be administered to trigger an immune reaction in a control system. He developed a therapy for hay fever using pollen extracts from grasses, flowers, and trees to desensitize the immune system to these allergens. In 1940, ALK introduced the first specific immunotherapy (SIT) for protection against pollen allergies. ALK-Abello A/S is a leading provider of allergen-based therapeutics and diagnostic tests for allergic diseases. The company offers two main products: allergen immunotherapies and diagnostic tests for allergic diseases. These products are offered in 28 countries worldwide, and the company is the largest provider of allergen-based therapeutics in Europe. ALK-Abello A/S operates three main divisions: allergen immunotherapies, diagnostic products, and other specialty products. The allergen immunotherapies are based on allergen extracts and aim to train the immune system to tolerate allergens by administering a small amount that is enough to trigger an immune response but not cause an allergic reaction. These therapies are used for various allergic diseases, including hay fever, asthma, and allergic skin conditions. The diagnostic products of ALK-Abello A/S are used for the diagnosis of allergic diseases. There are different types of diagnostic tests, including skin tests, in vitro diagnostic tests, and specific IgE tests (blood tests). Other specialty products of ALK-Abello A/S include products for the treatment of specific allergies or diseases related to allergies. Examples include adrenaline auto-injectors for the treatment of anaphylactic shock and nasal sprays for the treatment of hay fever. In summary, ALK-Abello A/S is a leading provider of allergy products and therapies, with a long history in the development of allergen-based therapeutics. The company operates three main divisions and offers a wide range of products that can be used for the diagnosis and treatment of allergic diseases. ALK-Abello A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing ALK-Abello A/S's Equity

ALK-Abello A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ALK-Abello A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ALK-Abello A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ALK-Abello A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ALK-Abello A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ALK-Abello A/S Stock

What is the equity of ALK-Abello A/S this year?

ALK-Abello A/S has equity of 4.45 B DKK this year.

What was the equity of ALK-Abello A/S compared to the previous year?

The equity of ALK-Abello A/S has increased/decreased by 11.51% increased compared to the previous year.

What impact does a high equity have on investors of ALK-Abello A/S?

A high equity is advantageous for investors of ALK-Abello A/S as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of ALK-Abello A/S?

A low equity can be a risk for investors of ALK-Abello A/S, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of ALK-Abello A/S affect the company?

An increase in equity of ALK-Abello A/S can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of ALK-Abello A/S affect the company?

A reduction in equity of ALK-Abello A/S can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of ALK-Abello A/S?

Some factors that can affect the equity of ALK-Abello A/S include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of ALK-Abello A/S so important for investors?

The equity of ALK-Abello A/S is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can ALK-Abello A/S take to change the equity?

To change equity, ALK-Abello A/S can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does ALK-Abello A/S pay?

Over the past 12 months, ALK-Abello A/S paid a dividend of 5 DKK . This corresponds to a dividend yield of about 3.48 %. For the coming 12 months, ALK-Abello A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of ALK-Abello A/S?

The current dividend yield of ALK-Abello A/S is 3.48 %.

When does ALK-Abello A/S pay dividends?

ALK-Abello A/S pays a quarterly dividend. This is distributed in the months of April, April, April, April.

How secure is the dividend of ALK-Abello A/S?

ALK-Abello A/S paid dividends every year for the past 5 years.

What is the dividend of ALK-Abello A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is ALK-Abello A/S located?

ALK-Abello A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALK-Abello A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALK-Abello A/S from 3/20/2017 amounting to 5 DKK, you needed to have the stock in your portfolio before the ex-date on 3/16/2017.

When did ALK-Abello A/S pay the last dividend?

The last dividend was paid out on 3/20/2017.

What was the dividend of ALK-Abello A/S in the year 2023?

In the year 2023, ALK-Abello A/S distributed 0 DKK as dividends.

In which currency does ALK-Abello A/S pay out the dividend?

The dividends of ALK-Abello A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ALK-Abello A/S

Our stock analysis for ALK-Abello A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALK-Abello A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.